These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 16172229)

  • 1. Total and percent free prostate-specific antigen levels among U.S. men, 2001-2002.
    Saraiya M; Kottiri BJ; Leadbetter S; Blackman D; Thompson T; McKenna MT; Stallings FL
    Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2178-82. PubMed ID: 16172229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men.
    Culp S; Porter M
    BJU Int; 2009 Nov; 104(10):1457-61. PubMed ID: 19522868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal.
    Welch HG; Schwartz LM; Woloshin S
    J Natl Cancer Inst; 2005 Aug; 97(15):1132-7. PubMed ID: 16077071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The distribution of serum prostate-specific antigen levels among American men: implications for prostate cancer prevalence and screening.
    Porter MP; Stanford JL; Lange PH
    Prostate; 2006 Jul; 66(10):1044-51. PubMed ID: 16598738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies combining total and percent free prostate specific antigen for detecting prostate cancer: a prospective evaluation.
    Gann PH; Ma J; Catalona WJ; Stampfer MJ
    J Urol; 2002 Jun; 167(6):2427-34. PubMed ID: 11992051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate specific antigen reference ranges in Saudi men.
    Kamal BA; Ali GA; Taha SA
    Saudi Med J; 2003 Jun; 24(6):665-8. PubMed ID: 12847600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of prostate specific antigen testing for prostate cancer in elderly men.
    Dyche DJ; Ness J; West M; Allareddy V; Konety BR
    J Urol; 2006 Jun; 175(6):2078-82. PubMed ID: 16697807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Demographics and health-related factors of men receiving prostate-specific antigen screening in Utah.
    Merrill RM
    Prev Med; 2001 Dec; 33(6):646-52. PubMed ID: 11716662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen and free prostate-specific antigen in the early detection of prostate cancer: do combination tests improve detection?
    Etzioni R; Falcon S; Gann PH; Kooperberg CL; Penson DF; Stampfer MJ
    Cancer Epidemiol Biomarkers Prev; 2004 Oct; 13(10):1640-5. PubMed ID: 15466981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological variation of total, free and percent free serum prostate specific antigen levels in screening volunteers.
    Ornstein DK; Smith DS; Rao GS; Basler JW; Ratliff TL; Catalona WJ
    J Urol; 1997 Jun; 157(6):2179-82. PubMed ID: 9146610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate specific-antigen distribution in asymptomatic Canadian men with no clinical evidence of prostate cancer.
    Chun FK; Perrotte P; Briganti A; Benayoun S; Lebeau T; Ramirez A; Lewinshtein DJ; Valiquette L; Guay JP; Karakiewicz PI
    BJU Int; 2006 Jul; 98(1):50-3. PubMed ID: 16831142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of percent free PSA for prostate cancer detection in men with a total PSA of 4-10 ng/ml.
    Bermúdez-Tamayo C; Martín Martín JJ; González Mdel P; Pérez Romero C
    Urol Int; 2007; 79(4):336-44. PubMed ID: 18025853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer.
    Chun FK; Hutterer GC; Perrotte P; Gallina A; Valiquette L; Benard F; McCormack M; Briganti A; Ionescu C; Jeldres C; Guay JP; Saad F; Karakiewicz PI
    BJU Int; 2007 Jul; 100(1):37-41. PubMed ID: 17488305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlates of prostate-specific antigen testing in a large multiethnic cohort.
    Haque R; Van Den Eeden SK; Jacobsen SJ; Caan B; Avila CC; Slezak J; Sternfeld B; Loo RK; Quinn VP
    Am J Manag Care; 2009 Nov; 15(11):793-9. PubMed ID: 19895183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population-based screening for prostate cancer by measuring total serum prostate-specific antigen in Iran.
    Hosseini SY; Moharramzadeh M; Ghadian AR; Hooshyar H; Lashay AR; Safarinejad MR
    Int J Urol; 2007 May; 14(5):406-11. PubMed ID: 17511722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
    Jegu J; Tretarre B; Grosclaude P; Rebillard X; Bataille V; Malavaud B; Iborra F; Salama G; Rischmann P; Villers A
    Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years.
    Sun L; Moul JW; Hotaling JM; Rampersaud E; Dahm P; Robertson C; Fitzsimons N; Albala D; Polascik TJ
    BJU Int; 2007 Apr; 99(4):753-7. PubMed ID: 17244286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of reducing the prostate-specific antigen threshold and including isoform reflex tests on the performance characteristics of a prostate-cancer detection programme.
    Roddam AW; Hamdy FC; Allen NE; Price CP;
    BJU Int; 2007 Sep; 100(3):514-7. PubMed ID: 17542987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower.
    Walz J; Haese A; Scattoni V; Steuber T; Chun FK; Briganti A; Montorsi F; Graefen M; Huland H; Karakiewicz PI
    Cancer; 2008 Nov; 113(10):2695-703. PubMed ID: 18853417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current and projected annual direct costs of screening asymptomatic men for prostate cancer using prostate-specific antigen.
    Krahn MD; Coombs A; Levy IG
    CMAJ; 1999 Jan; 160(1):49-57. PubMed ID: 9934343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.